Arcadia Biosciences Inc (RKDA) - Forward Price-to-Revenue Multiple

Arcadia Biosciences is developing the GoodWheat product line, utilizing non-GMO methods to create low-glycemic index grains. The company's projected P/S ratio demonstrates market confidence in management, while 0.20 represents a fresh level value. Laboratory robotization and AI-driven gene analysis are accelerating breeding, and the high margins of functional components provide operational leverage when entering major retail chains.

arcadiabio.com - RKDA Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for arcadiabio.com (RKDA)

- stock price and consensus target price:

Stock Quotes Arcadia Bio|RKDA - Fair Value Consensus

- market capitalization indicators:

Market Valuation Arcadia Biosciences Corp|RKDA - Aggregate Business Value

- business book valuation details:

Book Value per Share Arcadia Biosciences|RKDA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio arcadiabio.com|RKDA - Cumulative Company Assets

- debt obligations and liquidity statistics:

- financial results and valuation multiples details:

RKDA - Company Net Income|Projected Future Earnings Arcadia Biosciences|RKDA - Market Cap to Net Income Ratio|Projected Price to Earnings Arcadia Biosciences Inc|RKDA - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Arcadia Biosciences|RKDA - Operating profit EBITDA|Earnings per share for the last twelve months Arcadia Biosciences|RKDA - Earnings per share for the trailing year|Quarterly EPS earnings growth arcadiabio.com|RKDA - Net earnings per share growth this year|Earnings growth forecast for next year Arcadia Biosciences

- revenue and sales details:

RKDA - Revenue and Sales Volume|Projected Sales Volume Arcadia Biosciences|RKDA - Market Cap to Revenue Ratio|Forward P/S Multiple Arcadia Bio

Fundamental company valuation:RKDA (arcadiabio.com)

Forward P/S measures market capitalization relative to expected revenue, reflecting valuation sensitivity to the cost of capital and the risk of overpaying for future flows. Analyzing the forward P/S metric for Arcadia Biosciences (RKDA) is critical: an inflated ratio amid stagnating wheat sales and workforce reductions signals a high probability of a sharp price correction if forecast targets are not met.

Competitor analysis

IDEXX Lab - Forward Price-to-Revenue Multiple|Forward Price to Sales TRMB|NEOG: Forward Price-to-Revenue Multiple|Zhengye Biotechnology - Price to Expected Revenue Ratio|YMT: Forward P/S Multiple|Market Cap to Future Revenue Ratio Bioceres (BIOX)|GRWG (growgeneration.com) - Forward P/S Multiple|RYM: Forward Price to Sales|Forward P/S Multiple CBUS|WFCF (Where Food Comes From Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio ageagle.com UAVS|TGHL: Market Cap to Projected Revenue|IPW - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Hydrofarm|ceaindustries.com (BNC) - Price-to-Projected Revenue Ratio|UGRO (Urban-gro) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio N2OFF Inc.|Market Cap to Future Revenue Ratio AgriFORCE Growing Systems AGRI|Forward P/S Multiple AGFY|Benson Hill, Inc. (BHIL) - Projected Price to Revenue|CEA Industries, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TIO (Tingo Group, Inc.)